Zoetis Research and Development Expenses 2011-2025 | ZTS

Zoetis research and development expenses for the twelve months ending March 31, 2025 were $681M, a 7.41% increase year-over-year.

  • Zoetis annual research and development expenses for 2024 were $0.686B, a 11.73% increase from 2023.
  • Zoetis annual research and development expenses for 2023 were $0.614B, a 13.91% increase from 2022.
  • Zoetis annual research and development expenses for 2022 were $0.539B, a 6.1% increase from 2021.

Zoetis Research and Development Expenses 2011-2025 | ZTS

  • Zoetis annual research and development expenses for 2024 were $0.686B, a 11.73% increase from 2023.
  • Zoetis annual research and development expenses for 2023 were $0.614B, a 13.91% increase from 2022.
  • Zoetis annual research and development expenses for 2022 were $0.539B, a 6.1% increase from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.3B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$46.1B
BeOne Medicines - (ONC)$31.9B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$21.3B
Merck (MKKGY)$17.2B
Shionogi (SGIOY)$14.6B
United Therapeutics (UTHR)$13.7B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$10.9B
Stevanato Group S.p.A (STVN)$8B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.7B
Madrigal Pharmaceuticals (MDGL)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B